Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.63 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.60 |
| ▸ | ITGAV | P06756 | 2/20 | 0.60 |
| ▸ | TGM2 | P21980 | 5/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874103 | 1.00 | SIRT2 (0.65) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| Hydrochloric Acid SCHEMBL1162427 | 0.99 | SIRT2 (0.64) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| SCHEMBL1162281 | 0.96 | SIRT2 (0.60) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| SCHEMBL20272626 | 0.95 | SIRT2 (0.60) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| Hydrochloric Acid SCHEMBL1162135 | 0.95 | SIRT2 (0.59) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| SCHEMBL21019116 | 0.91 | FOLH1 (0.66) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| SCHEMBL28832879 | 0.91 | SIRT2 (0.56) | SIRT2SIRT1FOLH1ITGB3CTSL | |
| SCHEMBL8387978 | 0.91 | FOLH1 (0.65) | SIRT2SIRT1FOLH1ITGB3ITGAV | |
| Hydrochloric Acid SCHEMBL1161917 | 0.90 | SIRT2 (0.55) | SIRT2SIRT1FOLH1ITGB3TGM2 | |
| SCHEMBL12091751 | 0.88 | FOLH1 (0.64) | SIRT2SIRT1FOLH1ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | SIRT2 2436/4885SIRT1 1811/4885FOLH1 783/4885 |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | SIRT2 930/4885SIRT1 1123/4885FOLH1 1818/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | SIRT2 930/4885SIRT1 1123/4885FOLH1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.